InvestorsHub Logo

H2R

Followers 42
Posts 2156
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: midastouch017 post# 1034

Thursday, 08/17/2017 10:26:54 AM

Thursday, August 17, 2017 10:26:54 AM

Post# of 3870
Thanks Midastouch,

They continue to execute on their plans, keep cash in the coffers, prepare for this GI product, a deep pipeline with Ph III trials including Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)and an Estimated Completion date of Sept '17!

This continues to looking good.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News